Clinical-stage ADC innovator with suite of class-leading ADCs based on tumor-selective payload release & activation: 2 ADCs in clinic, (HER2, CD19); IKS04 (GI cancers) approaching IND; early pipeline of ProAlk-driven ADCs incorporating novel payload MoA